Alli spokeswoman Judd share her progress with private concert
PARSIPPANY, N.J. Alli spokeswoman Wynonna Judd held a private performance July 11 at the Country Music Hall of Fame in Nashville to celebrate her progress since starting the Alli method, which has included dropping two dress sizes. The concert was held exclusively for 50 sweepstakes winners.
“In the past few months, I’ve learned to look at weight loss with a fresh approach that includes better nutrition, exercise and emotional support,” Judd said. “I am so encouraged by my progress and am loving the way I feel. I was thrilled to perform for and fellowship with an audience that is also working toward a healthier way of living.”
Wynonna announced her partnership with GlaxoSmithKline Consumer Healthcare on its weight-loss Alli brand in January. Judd appears in the brand’s national advertising campaign and is participating in a series of promotions throughout the year.
“The Alli Method is about succeeding through healthy, gradual weight loss,” stated Rachel Ferdinando, VP weight control for GlaxoSmithKline Consumer Healthcare. “We’re proud of [Judd’s] progress and to be her partner in her journey to develop a healthy relationship with food. She is an amazing woman and her accomplishments both on and off the stage make her an inspiration to people everywhere.”
Perrigo receives FDA approval for smoking-cessation lozenges
ALLEGAN, Mich. Perrigo on Monday announced that it has received Food and Drug Administration approval for its over-the-counter coated nicotine polacrilex lozenge, 2 mg and 4 mg, in cherry and cinnamon flavors.
The new products will be marketed under store brand labels and are comparable with GlaxoSmithKline’s smoking cessation product Commit lozenge.
“These two approvals expand our exclusive position in the store brand nicotine lozenge category,” stated Perrigo chairman and CEO Joseph Papa. “The expanded range of smoking cessation products also includes coated mint and Fruit Chill-flavored gum, uncoated gum and lozenges.”
The smoking cessation category is selling at an annual rate estimated at approximately $1 billion at all retail outlets, Perrigo reported.
Study finds that use of Premarin Vaginal Cream relieves vaginal atrophy symptoms
COLLEGEVILLE, Pa. A study published in the July/August issue of Menopause: The Journal of the North American Menopause Society supported daily and twice-weekly use of Premarin (conjugated estrogens) Vaginal Cream to relieve symptoms of moderate-to-severe vulvar and vaginal atrophy, including painful intercourse, Wyeth Pharmaceuticals announced Monday.
In this study, dyspareunia (painful intercourse) was the most bothersome symptom at baseline (57%) followed by vaginal dryness, itching and burning. Unlike hot flashes or night sweats, signs and symptoms of vaginal atrophy have been shown to increase over time in postmenopausal women.
“Based on market research data, we understand that many postmenopausal women are not discussing their symptoms with their health care professionals,” stated Gloria Bachmann, lead study author and director of the Women’s Health Institute at the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. “We are encouraged by this 52-week data that showed twice-weekly use of Premarin Vaginal Cream was sufficient to provide relief from painful intercourse due to menopause. The study also supported daily use of Premarin Vaginal Cream 0.5 g to treat postmenopausal vaginal dryness. This information should aid postmenopausal women and their health care professionals in discussing whether and how they may treat vaginal atrophy.”